A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
- Cancer
- Hepatocellular Carcinoma (HCC)
- Lung Cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Breast Cancer
- Triple Negative Breast Cancer
- Small Cell Lung Carcinoma
- Bladder Cancer
- Urothelial Carcinoma
Completed
- Ansan-si
- Anyang
- Bucheon
- Busan
- Chuncheon-si
- Daegu
- Daejeon
- gangneung
- Hwaseong-si
- Hwasun
- Iksan
- Jeonju
- Seongnam-si
- Seoul
- Suwon
- Ulsan
- Weonju
- Wonju-si
- Yangsan
NCT03232593 ML39313
Study Summary
This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the drug label approved by the MFDS in Korea.
Post-Marketing Surveillance of Tecentriq in MFDS-Approved Indication(s)
Eligibility Criteria
- Participants who are administered with atezolizumab for the locally approved indications
- Participants with a known hypersensitivity to atezolizumab or to any of the excipients
For the latest version of this information please go to www.forpatients.roche.com